Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years

Viking Therapeutics is advancing its weight-loss drug candidates, particularly SC VK2735, through Phase 3 trials with promising clinical results. Under a bullish scenario with $1 billion in 2031 revenue, a $1,000 investment could grow to approximately $1,875 by 2031 (13.4% annualized returns). However, significant risks exist including potential Phase 3 trial failures, increased competition, market growth uncertainties, and potential dilutive financing needs.

10/20/2026, 10:00 AM • The Motley Fool

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.

Viking Therapeutics raised $575 million through a stock offering and convertible notes to fund multiple phase 3 trials for its obesity drug VK2735 and pipeline development. The company expects to have cash through at least 2028, with key trial results expected between 2027-2028. The company's future depends on VK2735's clinical success.

10/18/2026, 6:30 PM • The Motley Fool

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight

Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.

10/15/2026, 1:00 PM • GlobeNewswire

4 High-Risk Stocks Built for Big Returns

The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize.

10/14/2026, 6:08 AM • The Motley Fool

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

Oppenheimer analyst Jay Olson raised his price target on Viking Therapeutics to $120 from $100, implying a potential quadrupling from the current $28.50 price. The bullish call is based on positive maintenance trial data for VK2735, a GLP-1 and GIP agonist drug, which increased the probability of success from 80% to 90%. Wall Street consensus projects VK2735 could generate $1.5 billion in 2030 sales rising to $6.5 billion by 2035, potentially capturing market share from Eli Lilly's tirzepatide, which is expected to reach $80 billion in total sales by 2030.

10/12/2026, 7:22 AM • The Motley Fool

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Viking Therapeutics is advancing its oral weight-loss drug VK2735 to Phase 3 trials, showing 12.2% weight loss in Phase 2 testing. However, the company faces significant competitive challenges from established players like Eli Lilly's Foundayo, which demonstrated better tolerability with lower discontinuation rates. While Viking's injectable formulation shows promise with potential monthly dosing differentiation, the biotech will struggle to gain market traction in an increasingly crowded obesity drug market dominated by incumbents.

10/10/2026, 12:15 PM • The Motley Fool

Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock

Eli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations.

10/05/2026, 4:20 PM • The Motley Fool

Here Are My Top 4 Stocks to Buy in October

The article recommends four stocks for October investment: Viking Therapeutics for its unique monthly-dose GLP-1 weight loss drug candidate in a market expected to reach $200 billion by 2030; Alphabet for its dominant position in cloud computing AI services with 82% YoY growth and gaining market share; SoFi Technologies for strong revenue growth (40% YoY) and customer expansion despite recent setbacks; and MercadoLibre for its Amazon-like growth trajectory in Latin America with 50% YoY revenue growth despite margin pressures from free shipping initiatives.

10/05/2026, 8:24 AM • The Motley Fool

Prediction: This Stock Could Double Over the Next 5 Years

Viking Therapeutics' weight loss drug VK2735 shows strong clinical promise with potential for dual-formulation therapy (injectable followed by oral maintenance). The company raised $500 million to fund pipeline development. With the obesity drug market projected to reach $77 billion by 2030, even a small 1.4% market share could generate $1.2 billion in revenue for Viking's $4 billion market cap, suggesting significant upside potential, though clinical trial risks remain.

10/02/2026, 6:15 AM • The Motley Fool

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Viking Therapeutics released impressive clinical trial results for its weight-loss drug VK2735, showing 16-19% body weight loss and strong maintenance results. However, Eli Lilly's stock barely moved because the company has its own robust maintenance strategies (Foundayo and dose reduction approaches) and a deeper pipeline. While Viking could become a competitor in the growing weight-loss market, it still needs to confirm results in larger Phase 3 trials, and Eli Lilly remains the safer, more established choice.

09/29/2026, 5:30 PM • The Motley Fool

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

Viking Therapeutics' GLP-1 drug VK2735 showed promising clinical trial results with 16-19% weight loss and strong maintenance rates, causing the stock to surge. While riskier than Eli Lilly due to its smaller $4.1B market cap and lack of approved drugs, Viking could offer significant upside potential through drug approval or acquisition by a larger healthcare company.

09/28/2026, 9:01 AM • The Motley Fool

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.

09/25/2026, 6:05 AM • The Motley Fool

Here's Why Viking Therapeutics Shares Slumped Today

Viking Therapeutics stock declined 14.5% following the announcement of a capital raise ($275 million in common stock and $225 million in convertible notes), not due to negative trial results. The company's maintenance study for its weight-loss drug VK2735 showed positive results, prompting management to upsize the offering from initial plans. The stock correction reflects profit-taking after trading above $41 prior to the $35 offering price announcement.

09/24/2026, 11:30 AM • The Motley Fool

Why Viking Therapeutics Stock Skyrocketed on Tuesday

Viking Therapeutics' stock surged 35.67% after announcing positive clinical trial results for its obesity drug VK2735. Participants lost 16-19% of body weight over 21 weeks and maintained up to 97% of weight loss with flexible dosing schedules. The drug showed strong tolerability with low discontinuation rates, positioning Viking as a potential challenger in the rapidly expanding obesity drug market projected to reach $150 billion by 2035.

09/23/2026, 12:04 AM • The Motley Fool

3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong

While three Wall Street analysts have bullish $100 price targets on Viking Therapeutics (implying a tripling), the author argues this is overly optimistic. Viking's weight-loss drug VK2735 would need near-flawless phase 3 data showing 23-26% mean weight loss to justify such gains, and any clinical setback could sink the stock. The author recommends only risk-tolerant investors consider a small position.

09/03/2026, 4:30 PM • The Motley Fool